XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a secondline setting involving the sequential administration of XELOX and XELIRI

Author：                        

Publisher： Spandidos Publications

ISSN： 2049-9469

Source： Molecular and Clinical Oncology, Vol.2, Iss.5, 2014-01, pp. : 827-832

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a firstline treatment for Japanese patients with metastatic colorectal cancer

By                    

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 134-138

Spandidos Publications

Access to resources Recommend Favorite

Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the firstline treatment of metastatic colorectal cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 166-170

Spandidos Publications

Access to resources Recommend Favorite

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin or irinotecanbased treatment

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 356-362

Spandidos Publications

Access to resources Recommend Favorite

Phase II study on the combination of irinotecan plus cisplatin as a secondline therapy in patients with advanced or recurrent gastric cancer

By                    

Molecular and Clinical Oncology, Vol. 1, Iss. 4, 2013-01 ,pp. : 749-752

Spandidos Publications

Access to resources Recommend Favorite

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

By Suzuki   Hirashima   Kobayashi   Okamoto   Matsuura   Tamiya   Morishita   Okafuji   Shiroyama   Morimura   Morita   Kawase  

Molecular and Clinical Oncology, Vol. 1, Iss. 3, 2013-01 ,pp. : 480-482

Spandidos Publications

Access to resources Recommend Favorite